State Of Wisconsin Investment Board Savara Inc Transaction History

State Of Wisconsin Investment Board

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.66 - $5.34 $4,984 - $7,273	-1,362 Reduced 2.48%	53,640 $216,000
Q1 2024 May 14, 2024	BUY	$4.19 - $5.59 $230,458 - $307,461	55,002 New	55,002 $273,000
Q3 2019 Nov 12, 2019	SELL	$2.16 - $3.2 $85,752 - $127,040	-39,700 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.37 - $11.7 $2,133 - $10,530	900 Added 2.32%	39,700 $94,000
Q1 2019 May 13, 2019	BUY	$6.71 - $8.6 $59,719 - $76,540	8,900 Added 29.77%	38,800 $286,000
Q4 2018 Feb 11, 2019	BUY	$6.27 - $10.92 $24,453 - $42,588	3,900 Added 15.0%	29,900 $226,000
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $272,740 - $334,620	26,000 New	26,000 $290,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $368M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.